Guidance, NICE advice and quality standards in development | Guidance

Showing 231 to 240 of 389

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]	Technology appraisal guidance	TBC
Obicetrapib and obicetrapib–ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID6519]	Technology appraisal guidance	14 October 2026
Obinutuzumab for treating serologically active extra-renal lupus [ID6670]	Technology appraisal guidance	TBC
Obsessive-compulsive disorder and body dysmorphic disorder	Quality standard	16 February 2027
Obsessive-compulsive disorder and body dysmorphic disorder: assessment and management	NICE guideline	16 February 2027
Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]	Technology appraisal guidance	TBC
Olezarsen for treating familial chylomicronaemia syndrome [ID6585]	Technology appraisal guidance	19 August 2026
Omburtamab for treating relapsed neuroblastoma [ID1664]	Technology appraisal guidance	TBC
Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease [TSID11941]	Technology appraisal guidance	TBC
Optical Coherence Tomography to guide percutaneous coronary intervention	Interventional procedures guidance	TBC